A detailed history of Steward Partners Investment Advisory, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 513 shares of HALO stock, worth $24,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares
513
Previous 313 63.9%
Holding current value
$24,311
Previous $16,000 81.25%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.3 - $64.42 $10,260 - $12,884
200 Added 63.9%
513 $29,000
Q2 2024

Aug 08, 2024

BUY
$37.81 - $52.4 $491 - $681
13 Added 4.33%
313 $16,000
Q1 2023

May 15, 2023

SELL
$32.86 - $55.7 $32,860 - $55,700
-1,000 Reduced 76.92%
300 $11,000
Q2 2022

Aug 04, 2022

BUY
$37.35 - $48.3 $48,555 - $62,789
1,300 New
1,300 $57,000
Q4 2021

Feb 08, 2022

SELL
$31.82 - $40.75 $11,137 - $14,262
-350 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$38.84 - $51.31 $19,420 - $25,655
-500 Reduced 58.82%
350 $16,000
Q1 2021

May 14, 2021

BUY
$39.51 - $51.45 $19,755 - $25,725
500 Added 142.86%
850 $35,000
Q4 2020

Feb 11, 2021

BUY
$25.81 - $43.62 $9,033 - $15,267
350 New
350 $15,000
Q1 2020

Apr 29, 2020

SELL
$13.9 - $21.83 $33,360 - $52,391
-2,400 Closed
0 $0
Q3 2019

Oct 30, 2019

SELL
$15.2 - $17.69 $7,220 - $8,402
-475 Reduced 16.52%
2,400 $37,000
Q2 2019

Jul 25, 2019

BUY
$14.75 - $17.26 $42,406 - $49,622
2,875 New
2,875 $49,000
Q4 2018

Jan 15, 2019

SELL
$13.33 - $18.66 $41,722 - $58,405
-3,130 Closed
0 $0
Q3 2018

Oct 23, 2018

SELL
$16.68 - $18.41 $166 - $184
-10 Reduced 0.32%
3,130 $57,000
Q2 2018

Jul 20, 2018

BUY
$16.87 - $20.3 $52,971 - $63,742
3,140 New
3,140 $53,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.6B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.